IFRX News and Press, InflaRx N.V. From 06/28/23

2023-06-28 07:50:53 ET clinical-stage biopharmaceutical company InflaRx N.V. ( NASDAQ: IFRX ) appoints Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmac...

Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug development Dr. Chong to lead clinical development of InflaRx’s portfolio of C5a/C5aR inhibitors JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasd...

2023-06-21 20:37:59 ET Summary Today, we take our first look at InflaRx N.V. since 2021. The shares have largely marked time since our initial look at them, but the company just got FDA Emergency Use Authorization for its Covid treatment. Does that meaningfully change the dyna...

Gohibic is now commercially available for hospitals in the U.S. Gohibic can be used under an Emergency Use Authorization (EUA) granted by the FDA for treatment of certain critically ill COVID-19 patients JENA, Germany, June 21, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX),...

2023-05-11 09:42:12 ET InflaRx press release ( NASDAQ: IFRX ): Q1 GAAP EPS of -€0.25. As of March 31, 2023, the Company had cash and cash equivalents and marketable securities amounting to €72.3 million. For further details see: InflaRx GAAP EP...

Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) for Gohibic (vilobelimab) for treatment of critically ill COVID-19 patients Gohibic planned to be available to patients in the U.S. within the next few weeks Phase III study with vilobelimab i...

JENA, Germany, April 18, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that, in connection with its previously announced c...

JENA, Germany, April 14, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has completed its underwritten public offer...

2023-04-12 12:55:56 ET Gainers: National CineMedia ( NCMI ) +151% . TESSCO Technologies Incorporated ( TESS ) +87% . Guardforce AI ( GFAI ) +51% . Bullfrog AI Holdings ( BFRG ) +32% . Altamira Therapeutics ( CYTO ) +28% . Tri...

2023-04-12 10:03:10 ET Gainers: Altamira Therapeutics ( CYTO ) +74% . Arrowhead Pharmaceuticals ( ARWR ) +11% . Procaps Group ( PROC ) +11% . Tempest Therapeutics ( TPST ) +11% . Meihua International Medical Technologies ( MHUA )...